(Q58971260)

English

Bisphosphonates

article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17117298%20AND%20SRC:MED&resulttype=core&format=json

22 December 2019

1 reference

Europe PubMed Central

Bisphosphonates (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17117298%20AND%20SRC:MED&resulttype=core&format=json

22 December 2019

Michael McClung

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17117298%20AND%20SRC:MED&resulttype=core&format=json

22 December 2019

author name string

Michael McClung

1

0 references

publication date

1 August 2006

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17117298%20AND%20SRC:MED&resulttype=core&format=json

22 December 2019

Arquivos Brasileiros de Endocrinologia e Metabologia

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17117298%20AND%20SRC:MED&resulttype=core&format=json

22 December 2019

50

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17117298%20AND%20SRC:MED&resulttype=core&format=json

22 December 2019

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17117298%20AND%20SRC:MED&resulttype=core&format=json

22 December 2019

735-744

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17117298%20AND%20SRC:MED&resulttype=core&format=json

22 December 2019

Osteoporosis prevention, diagnosis, and therapy

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400018

21 January 2018

Bone quality--the material and structural basis of bone strength and fragility

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400018

21 January 2018

Markers of bone resorption predict hip fracture in elderly women: the EPIDOS Prospective Study

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400018

21 January 2018

Rationale for the use of alendronate in osteoporosis

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400018

21 January 2018

Mechanism of action of bisphosphonates

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400018

21 January 2018

Drugs used to treat osteoporosis: the critical need for a uniform nomenclature based on their action on bone remodeling

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400018

21 January 2018

Two-year efficacy and tolerability of risedronate once a week for the treatment of women with postmenopausal osteoporosis

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400018

21 January 2018

Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400018

21 January 2018

Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400018

21 January 2018

Ten years' experience with alendronate for osteoporosis in postmenopausal women

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400018

21 January 2018

Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis.

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400018

21 January 2018

The bone-remodeling transient: implications for the interpretation of clinical studies of bone mass change.

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400018

21 January 2018

Long-term risedronate treatment normalizes mineralization and continues to preserve trabecular architecture: sequential triple biopsy studies with micro-computed tomography

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400018

21 January 2018

Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400018

21 January 2018

Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group.

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400018

21 January 2018

Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400018

21 January 2018

Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400018

21 January 2018

Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group.

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400018

21 January 2018

Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group.

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400018

21 January 2018

Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400018

21 January 2018

Efficacy of risedronate on clinical vertebral fractures within six months.

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400018

21 January 2018

Risedronate rapidly reduces the risk for nonvertebral fractures in women with postmenopausal osteoporosis

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400018

21 January 2018

Seven years of treatment with risedronate in women with postmenopausal osteoporosis

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400018

21 January 2018

Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400018

21 January 2018

Relationship between changes in bone mineral density and vertebral fracture risk associated with risedronate: greater increases in bone mineral density do not relate to greater decreases in fracture risk

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400018

21 January 2018

Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate.

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400018

21 January 2018

Pretreatment levels of bone turnover and the antifracture efficacy of alendronate: the fracture intervention trial

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400018

21 January 2018

Randomized trial of effect of alendronate continuation versus discontinuation in women with low BMD: results from the Fracture Intervention Trial long-term extension

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400018

21 January 2018

Multinational, Placebo-Controlled, Randomized Trial of the Effects of Alendronate on Bone Density and Fracture Risk in Postmenopausal Women with Low Bone Mass: Results of the FOSIT Study

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400018

21 January 2018

Prevention of postmenopausal bone loss: six-year results from the Early Postmenopausal Intervention Cohort Study.

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400018

21 January 2018

Alendronate prevents loss of bone density associated with discontinuation of hormone replacement therapy: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400018

21 January 2018

Alendronate for the Treatment of Osteoporosis in Men

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400018

21 January 2018

Efficacy of risedronate in men with primary and secondary osteoporosis: results of a 1-year study

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400018

21 January 2018

Oral daily ibandronate prevents bone loss in early postmenopausal women without osteoporosis

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400018

21 January 2018

Intravenous ibandronate injections in postmenopausal women with osteoporosis: One-year results from the dosing intravenous administration study

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400018

21 January 2018

Treatment with once-weekly alendronate 70 mg compared with once-weekly risedronate 35 mg in women with postmenopausal osteoporosis: a randomized double-blind study

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400018

21 January 2018

Efficacy and tolerability of cyclical intravenous pamidronate in patients with low bone mass

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400018

21 January 2018

Intravenous zoledronic acid in postmenopausal women with low bone mineral density

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400018

21 January 2018

Long-term safety of bisphosphonate therapy for osteoporosis: a review of the evidence

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400018

21 January 2018

Upper gastrointestinal tract safety profile of alendronate: the fracture intervention trial

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400018

21 January 2018

Tolerability and compliance with risedronate in clinical practice

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400018

21 January 2018

Oral ibandronate in the management of postmenopausal osteoporosis: review of upper gastrointestinal safety

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400018

21 January 2018

Hypoparathyroidism unmasked by alendronate

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400018

21 January 2018

Bisphosphonate-induced hypocalcemia: report of 3 cases and review of literature

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400018

21 January 2018

Bisphosphonate treatment suppresses not only stochastic remodeling but also the targeted repair of microdamage

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400018

21 January 2018

Severely suppressed bone turnover: a potential complication of alendronate therapy

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400018

21 January 2018

Alendronate in the prevention of osteoporosis: 7-year follow-up

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400018

21 January 2018

Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400018

21 January 2018

Osteonecrosis of the jaws in patients treated with bisphosphonates - histomorphologic analysis in comparison with infected osteoradionecrosis.

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400018

21 January 2018

Clinical and diagnostic imaging of bisphosphonate-associated osteonecrosis of the jaws.

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400018

21 January 2018

Managing the care of patients with bisphosphonate-associated osteonecrosis: an American Academy of Oral Medicine position paper

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400018

21 January 2018

Efficacy of alendronate, a bisphosphonate, in the treatment of AVN of the hip. A prospective open-label study

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400018

21 January 2018

Bisphosphonate therapy improves the outcome of conventional periodontal treatment: results of a 12-month, randomized, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400018

21 January 2018

Effect of alendronate on periodontal disease in postmenopausal women: a randomized placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400018

21 January 2018

Toxic acute tubular necrosis following treatment with zoledronate (Zometa).

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400018

21 January 2018

Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, placebo-controlled extension trial

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400018

21 January 2018

Osteoporosis after solid organ and bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400018

21 January 2018

Prevention of bone loss in renal transplant recipients: a prospective, randomized trial of intravenous pamidronate

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400018

21 January 2018

Pamidronate in the prevention of chemotherapy-induced bone loss in premenopausal women with breast cancer: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400018

21 January 2018

Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400018

21 January 2018

Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400018

21 January 2018

Pamidronate in children with osteogenesis imperfecta: histomorphometric effects of long-term therapy

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400018

21 January 2018

Effect of alendronate therapy in children with osteogenesis imperfecta

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400018

21 January 2018

Proposals for prevention and management of steroid-induced osteoporosis in children and adolescents

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400018

21 January 2018

A prospective study of changes in bone turnover and bone density associated with regaining weight in women with anorexia nervosa

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400018

21 January 2018

Effects of risedronate on bone density in anorexia nervosa

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400018

21 January 2018

Alendronate for the treatment of osteopenia in anorexia nervosa: a randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400018

21 January 2018

Management of low bone mineral density in premenopausal women

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400018

21 January 2018

Changes in bone density and turnover after alendronate or estrogen withdrawal.

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400018

21 January 2018

Significant differential effects of alendronate, estrogen, or combination therapy on the rate of bone loss after discontinuation of treatment of postmenopausal osteoporosis. A randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400018

21 January 2018

Combination therapy with hormone replacement and alendronate for prevention of bone loss in elderly women: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400018

21 January 2018

Identifiers

10.1590/S0004-27302006000400018

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17117298%20AND%20SRC:MED&resulttype=core&format=json

22 December 2019

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17117298%20AND%20SRC:MED&resulttype=core&format=json

22 December 2019

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q58971260&oldid=2001577638"